Covıd-19 Hastalarında Nötrolizan Antikor Düzeyinin 6 Aylık Prospektif İzlemi
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
COVID-19 pandemisi tüm dünyayı halen etkilemektedir. Hastalıktan korunmada, reenfeksiyonların önlenmesinde ve aşı çalışmalarında humoral yanıtın aydınlatılması yol gösterici olmaktadır. Çalışmamızın amacı COVID-19 enfeksiyonu sonrası oluşan antikor yanıtları ve bunları etkileyen faktörleri belirlemektir.
Yöntem: Çalışmamıza COVID-19 PCR testi pozitif olan 100 hasta dahil edildi. Hastaların 7. gün, 15. gün , 30. gün 3. ay ve 6. ayda COVID-19 IgM ve IgG antikor düzeyleri takibi yapıldı. Hastaların yaşları, cinsiyetleri, komorbiditeleri, semptomları, BT sonuçları, laboratuvar değerleri ile antikor düzeyleri karşılaştırıldı.
Bulgular: Hastaların COVID-19 IgM ve IgG antikorları sırasıyla 7. günde % 69 ve % 49; 15. günde % 96 ve %98; 30. günde %76 ve % 98; 3. ayda % 65 ve %94; 6. ayda %35 ve %100 oranında pozitif saptandı.Halsizlik, öksürük, nefes darlığı, ishal semptomları olan hastalarda antikor düzeyleri yüksek bulundu. Göğüs BT’ de tutulumu olan hastalarda antikor düzeyleri daha yüksek saptandı. Yatan hastalarda ayaktan takip edilen hastalara göre antikor düzeyleri daha yüksek bulundu. Lenfosit sayısı, ALT, AST, D-dimer, fibrinojen, ferritin, CRP, prokalsitonin düzeyleri ile antikor düzeyleri arasında pozitif yönde korelasyon görüldü.
Sonuç: COVID-19 geçiren hastalarda büyük oranda nötrolizan antikorların oluştuğu ve 6 ay boyunca devamlılık gösterdiği bulundu. Hastalığı semptomatik geçirenler ve daha şiddetli geçirenlerde antikor düzeyleri daha yüksek bulundu.
The COVID-19 pandemic still affects the whole world. Clarifying the humoral response in guiding in disease prevention, prevention of reinfections and vaccine studies. The aim of our study is to determine the antibody responses that occur after COVID-19 infection and the factors affecting them. Method: One hundred patients with positivite COVID-19 PCR test were included in our study. COVID-19 IgM and IgG antibody levels of the patients were followed up on the 7th day, 15th day, 30th day, 3rd month and 6th month. Age, gender, comorbidities, symptoms, CT results, influenza and pneumococcal vaccines, transmission routes, laboratory values and antibody levels of the patients were compared. Results: COVID-19 IgM and IgG antibodies of the patients were positive, respectively, 69% and 49% on the 7; 96% and 98% at day 15; 76% and 98% at day 30; 65% and 94% at 3 months; at 6 months, 35% and 100%. Antibody levels were found to be higher in patients with symptoms of weakness, cough, shortness of breath, diarrhea. Antibody levels were found to be higher in patients with involvement in chest CT. Antibody levels were found to be higher in inpatients than in outpatients. There was a positive correlation between lymphocyte count, ALT, AST, D-dimer, fibrinogen, ferritin, CRP, procalcitonin levels and antibody levels. Conclusion: It was found that neutralizing antibodies were formed to a large extent in patients with COVID-19 and persisted for 6 months. Antibody levels were found to be higher in those who had symptomatic and more severe disease.
The COVID-19 pandemic still affects the whole world. Clarifying the humoral response in guiding in disease prevention, prevention of reinfections and vaccine studies. The aim of our study is to determine the antibody responses that occur after COVID-19 infection and the factors affecting them. Method: One hundred patients with positivite COVID-19 PCR test were included in our study. COVID-19 IgM and IgG antibody levels of the patients were followed up on the 7th day, 15th day, 30th day, 3rd month and 6th month. Age, gender, comorbidities, symptoms, CT results, influenza and pneumococcal vaccines, transmission routes, laboratory values and antibody levels of the patients were compared. Results: COVID-19 IgM and IgG antibodies of the patients were positive, respectively, 69% and 49% on the 7; 96% and 98% at day 15; 76% and 98% at day 30; 65% and 94% at 3 months; at 6 months, 35% and 100%. Antibody levels were found to be higher in patients with symptoms of weakness, cough, shortness of breath, diarrhea. Antibody levels were found to be higher in patients with involvement in chest CT. Antibody levels were found to be higher in inpatients than in outpatients. There was a positive correlation between lymphocyte count, ALT, AST, D-dimer, fibrinogen, ferritin, CRP, procalcitonin levels and antibody levels. Conclusion: It was found that neutralizing antibodies were formed to a large extent in patients with COVID-19 and persisted for 6 months. Antibody levels were found to be higher in those who had symptomatic and more severe disease.
Açıklama
Anahtar Kelimeler
COVID-19, Nötrolizan Antikor, Seroloji, COVID-19, Neutralizing Antibody, Serology
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Gürel, Z. (2022). Covıd-19 Hastalarında Nötrolizan Antikor Düzeyinin 6 Aylık Prospektif İzlemi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Dahili Tıp Bilimleri Bölümü Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Konya.
